Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

99 years and younger
All genders
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Learn More

UPCC 06923: An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors

99 years and younger
All genders
Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints) Please refer to the protocol, section 2.2 (Objectives and Endpoints)
Learn More

UPCC 08223: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

99 years and younger
All genders
This is a Phase Ib/II study in participants with advanced liver cancers. Cohort 1 - participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible …
Learn More

UPCC 25823 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

99 years and younger
All genders
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. We would like to rely on WCG …
Learn More

UPCC 17423: An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

99 years and younger
All genders
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment …
Learn More

UPCC 25523: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

99 years and younger
All genders
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline. We would like to rely on WCG as the IRB of record for this study.
Learn More

UPCC 50423: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who

99 years and younger
All genders
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT). We would like to …
Learn More

UPCC 16323: Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients with Resectable HPV-Negative Mucosal Head/Neck Squamous Cell Carcinoma (HNSCC)

99 years and younger
All genders
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
Learn More

S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

99 years and younger
All genders
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose …
Learn More

EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

99 years and younger
All genders
To examine whether the addition of nivolumab, a monoclonal antibody specific for human programmed death-1 (PD-1) receptor expressed on T cells, after chemoradiation can provide a survival benefit in patients with locally advanced high-risk anal cancer
Learn More
111 - 120 of 206